REGENXBIO Inc. (NASDAQ:RGNX) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET
Company Participants
Patrick Christmas - Chief Legal Officer
Vit Vasista - Chief Financial Officer
Ken Mills - President & Chief Executive Officer
Steve Pakola - Chief Medical Officer
Lejla Vajzovic - Associate Professor, Ophthalmology; and Director, Duke Vitreoretinal Fellowship Program and Lead Investigator
Peter Kaiser - Director, Center for Ocular Research and Evaluation, Cole Eye Institute, Cleveland Clinic.
Conference Call Participants
Lisa Walter - RBC Capital Markets
Andreas Argyrides - Wedbush Securities
Operator
Hello and thank you for standing by. Welcome to the Q3 2022 REGENXBIO Inc. Earnings Call and Update on ALTITUDE. [Operator Instructions]
It is now my pleasure to introduce Chief Legal Officer, Patrick Christmas.
Patrick Christmas
Good morning, and thank you for joining us today. Earlier this morning REGENXBIO released financial and operating results for the third quarter ended September 30, 2022. As well as new data from our ALTITUDE trial. The press releases and data presentation are available on our website at www.REGENXBIO.com
Today's conference call will include forward-looking statements regarding our financial outlook and our development of RGX-314 in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. And can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meeting.
Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and Management's Discussion and Analysis sections of REGENXBIO's Annual Report on Form 10-K for the full year ended December 31, 2021. And comparable risk factors section of REGENXBIO's quarterly reports on Form 10-Q which are on file with the Securities and Exchange Commission and available on the SEC's website.
Any information we provide on this conference call is provided only as of at only as of the date of this call November 3, 2022 and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.
Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided this preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.